Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Koti

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
British Journal of Cancer|April 1, 2015
A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancerM Koti, A Siu, I Clément, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2013
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myelomaThomas M Herndon, Albert Deisseroth, Edvardas Kaminskas, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
British Journal of Cancer|April 1, 2015
A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancerM Koti, A Siu, I Clément, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2013
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myelomaThomas M Herndon, Albert Deisseroth, Edvardas Kaminskas, et al.
Pageof 2